The Bronchiolitis in Hospitalized Infants Study

Bronchiolitis Clinical Trial

— BroncHI  

Official title:

The Bronchiolitis in Hospitalized Infants (BroncHI) Study: A Feasibility Trial Aimed to Identify and Treat Hospitalized Infants With Bronchiolitis Most at Risk for Recurrent Wheezing and Asthma

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05994183
• Other study ID #: 275605
• Status: Withdrawn
• Phase: Early Phase 1
• Start date: October 9, 2023
• Est. completion date: April 14, 2025

Study information

• Verified date: September 2023
• Source: IDeA States Pediatric Clinical Trials Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to determine whether it is possible to identify, enroll, and deliver the study intervention (the corticosteroid dexamethasone) in hospitalized infants with bronchiolitis.

Participants in this study will be given two doses of dexamethasone within 72 hours of enrollment, followed by 30 days of safety monitoring.

Results of this feasibility pilot study may be used to inform the design of a future randomized controlled trial, whose results in turn could induce a paradigm shift in acute management of bronchiolitis.

Description:

This is a open-label single-arm pilot study to assess feasibility of study procedures. The study population is infants <24 months of age, admitted with a physician diagnosis of non-RSV bronchiolitis that meet at least one of the following criteria: 1) history of breathing problems, 2) history of eczema, and/or 3) family history of asthma.

The primary objective is to assess the ability to administer 2 doses of dexamethasone to infants hospitalized with bronchiolitis meeting the inclusion criteria. The literature suggests that prompt intervention in the course of bronchiolitis disease is important for possibly altering the immune response and sequelae. Therefore, it is important that we are able to demonstrate the ability to initiate the intervention while the child is still hospitalized and complete the number of doses with the desired anti-inflammatory effect. We aim to successfully administer both doses of the study medication in 87% of infants enrolled.

Enrolling sites will recruit participants in collaboration with outpatient practices within Environmental influences on Child Health Outcomes (ECHO) Institutional Development Award (IDeA) States Pediatric Clinical Trials Network (ISPCTN) states that provide primary care services to children (<24 months old). Sites will serve a population base of at least 40% Medicaid/uninsured children, <60% non-Hispanic White children, or >40% of families residing in rural communities.

Participants will be enrolled on the study for approximately 30 days. While in the study they will receive dexamethasone at a dose of 0.6 mg/kg/dose orally (max 16 mg/dose) per day for 2 days. The 1st dose will be given while the infant is inpatient (within 24 hours following enrollment). The 2nd dose will be given on Day 2, either inpatient or at home. The time interval between doses will be between 12 and 48 hours. Participants will be followed for safety information 30 days (±4 days) after the 2nd dose.

The study duration is 24 months (2 months start-up, 17 months enrollment, 1 month follow-up, and 3 months close-out and data analysis).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 14, 2025
• Est. primary completion date: March 9, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 0 Months to 24 Months

Eligibility

Inclusion Criteria:

• Infants <24 months of age at time of enrollment

• Admitted to the hospitalist service with a diagnosis of bronchiolitis

• RSV and COVID-19 Negative

• At least one of the following clinical criteria:

• personal history of breathing problems

• personal history of eczema

• parental history of asthma

• Parental ability to speak and read English or Spanish

Exclusion Criteria:

• Preterm Infant (born at < 34 weeks' gestation)

• Diagnosis of asthma

• Known underlying heart failure, hypertension, gastrointestinal bleeding, liver disease, thyroid disease (per parental report and chart review)

• Currently taking corticosteroids (inhaled or oral) or have taken corticosteroids within 7 days prior to hospitalization (per parental report and chart review)

• Admission to the intensive care unit (ICU) at time of enrollment

• Participants (caregivers) who, in the view of the investigator, whom are unlikely able to comply with the protocol requirements

Related Conditions & MeSH terms

• Bronchiolitis

Intervention

Drug:
• Dexamethasone Oral
Dexamethasone 0.6 mg/kg/dose orally (max 16 mg/dose)

Locations

Country	Name	City	State
United States	Arkansas Children's Hospital	Little Rock	Arkansas
United States	University of Nebraska Medical Center	Omaha	Nebraska

Sponsors (3)

Lead Sponsor	Collaborator
IDeA States Pediatric Clinical Trials Network	National Institutes of Health (NIH), University of Nebraska

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants that receive 2 doses of dexamethasone per protocol.	A total of N=30 recruited participants will be enrolled into the study. In the primary objective, we expect 26 out of 30 (87%) participating infants will successfully receive 2 doses of dexamethasone per protocol.	Intervention: 72 hours; Follow-up: 30 days